Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7975855 | 0.98 | HTT (0.72) | HTTFGFR1POLBCYP1A2CYP3A4 | |
| SCHEMBL30402227 | 0.88 | HTT (0.88) | HTTFGFR1POLBMAPTKMT2A | |
| SCHEMBL3419279 | 0.88 | HTT (0.88) | HTTFGFR1POLBMAPTKMT2A | |
| SCHEMBL157265 | 0.86 | HTT (1.00) | HTTFGFR1 | |
| Benzene SCHEMBL14876970 | 0.86 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL4891428 | 0.84 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL467858 | 0.84 | HTT (0.96) | HTTFGFR1 | |
| Iodide SCHEMBL30645138 | 0.84 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL27724758 | 0.84 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL2531256 | 0.82 | HTT (0.78) | HTTFGFR1POLBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6162804-A | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2000-12-19 | — | — | US | claimed |
| CN-115215861-A | Aromatic heterocycle substituted alkyne compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-111978301-B | Benzimidazole compound with endothelial lipase inhibition effect and application thereof | 盐城师范学院 | 2022-08-02 | — | — | CN | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-2621913-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044537-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011151619-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE | SUMMIT CORPORATION PLC (GB) | 2011-12-08 | — | — | WO | disclosed |
| EP-0266558-A2 | 5-Alkylbenzimidazoles, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | HTT 1107/4885FGFR1 1543/4885POLB 118/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | HTT 1107/4885FGFR1 1543/4885POLB 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.